FindMyKOL

John Sarantopoulos, MD

Basic profile

Assistant professor of medicine, Division of Hematology-Oncology, UT Health San Antonio · Medical Oncology

ORCIDNone on fileNPI↗
✓ Itemized record
Region🇺🇸 San Antonio, TX · South Central · United StatesSpecialtyMedical OncologyFocusLymphoma+20
Active KOLFindMyKOL type: NationalLatest publicationNot yet indexedOnline presenceverified 2026Payments2021 onwardNIH funding2008–2026Why? →

John Sarantopoulos is Assistant professor of medicine, Division of Hematology-Oncology, UT Health San Antonio. ClinicalTrials.gov lists 8 registered studies matched to this name.

Overview

Updated 27 Oct 2026

John Sarantopoulos, M.D., is Assistant professor of medicine, Division of Hematology-Oncology, UT Health San Antonio. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 18 companies, 3 NIH-funded awards (2008–2026).

  • Top research focus: Lymphoma
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 18 companies

Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma4 trialsHodgkin Disease2 trialsKidney Cancer / RCC1 trialHepatobiliary Cancer1 trialLeukemia (AML/ALL/CML/CLL)1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialLymphoma, Non-Hodgkin1 trialLeukemia, Lymphocytic, Chronic, B-Cell1 trialLymphoma, Follicular1 trialBurkitt Lymphoma1 trialLymphoma, B-Cell, Marginal Zone1 trialWaldenstrom Macroglobulinemia1 trialMycosis Fungoides1 trialSezary Syndrome1 trialLymphoma, T-Cell1 trialLeukemia, Hairy Cell1 trialIntraocular Lymphoma1 trialLeukemia, Lymphoid1 trialLeukemia, T-Cell1 trialGranuloma1 trialLymphomatoid Granulomatosis1 trialNeuro-Oncology / Glioma1 trial

Research focus

OpenAlex concept fingerprint
LymphomaHodgkin DiseaseBurkitt LymphomaHepatobiliary CancerIntraocular LymphomaKidney Cancer / RCCLeukemia (AML/ALL/CML/CLL)Leukemia, Hairy CellLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidLeukemia, T-CellLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Non-HodgkinLymphoma, T-CellLymphomatoid GranulomatosisMycosis FungoidesNeuro-Oncology / GliomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSezary SyndromeWaldenstrom Macroglobulinemia

Drugs & molecules

across trials, industry payments and publications
Cabometyxgeneric · CabozantinibClinical trials—Industry payments263Publications—Braftovigeneric · EncorafenibClinical trials—Industry payments127Publications—Libtayogeneric · CemiplimabClinical trials—Industry payments84Publications—Padcevgeneric · EnfortumabClinical trials—Industry payments84Publications—Mektovigeneric · BinimetinibClinical trials—Industry payments19Publications—Lonsurfgeneric · Tipiracil / trifluridineClinical trials—Industry payments3Publications—Opdivogeneric · NivolumabClinical trials—Industry payments3Publications—Fotivdageneric · TivozanibClinical trials—Industry payments2Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments2Publications—1,1'-(9-(2-((1-Methylethyl)amino)ethyl)-9H-carbazole-3,6-diyl)bis(ethanone)Clinical trials1Industry payments—Publications—Bavenciogeneric · AvelumabClinical trials—Industry payments1Publications—Carvyktigeneric · Ciltacabtagene autoleucelClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Exelixis Inc.Clinical trials—Industry payments263Pfizer Inc.Clinical trials—Industry payments131Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments83Astellas Pharma US IncClinical trials—Industry payments46Seagen Inc.Clinical trials—Industry payments32Array Biopharma IncClinical trials—Industry payments3E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments3National Cancer Institute (NCI)Clinical trials3Industry payments—Taiho Oncology, Inc.Clinical trials—Industry payments3Aveo Pharmaceuticals, Inc.Clinical trials—Industry payments2Eisai Inc.Clinical trials—Industry payments2Janssen Biotech, Inc.Clinical trials—Industry payments2Myriad Genetic Laboratories, Inc.Clinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Blueprint Medicines CorporationClinical trials—Industry payments1Cao Pharmaceuticals Inc.Clinical trials1Industry payments—CelgeneClinical trials1Industry payments—CTI BioPharmaClinical trials1Industry payments—EMD Serono, Inc.Clinical trials—Industry payments1Genzyme CorporationClinical trials—Industry payments1IncuronClinical trials1Industry payments—John SarantopoulosClinical trials1Industry payments—Lei ZhengClinical trials1Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments1Spectrum Pharmaceuticals, IncClinical trials1Industry payments—Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials ↓
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 2008–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Oct 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

All 8 trial records: search, sort and filter.Explore →

Industry payments

Updated 27 Oct 2026

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

All 40 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    56%
    PD-1 inhibitor55.1%
    Pembrolizumab100%
    Part B, office-administered≥24 patients
    Cytochrome P450 17A1 Inhibitor0.5%
    Abiraterone Acetate100%
    Part D≥16 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    26.2%
    Other antiemetics19.3%
    Fosaprepitant100%
    Part B, office-administered≥15 patients
    Serotonin-3 Receptor Antagonist5.5%
    Ondansetron hydrochloride66%Palonosetron hcl32%Ondansetron Hcl2%
    Part D + Part B<11 patients

    + 3 more classes in this area

  • Musculoskeletal

    11.3%
    RANK Ligand Inhibitor10.9%
    Denosumab100%
    Part B, office-administered≥15 patients
    Bisphosphonate0.4%
    Zoledronic acid100%
    Part B, office-administered≥13 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Oct 2026

3 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:

All 10 award records: search, sort and filter.Explore →

Online presence

Updated 27 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/john-sarantopoulos-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    providers.uthscsa.edu/providers/john-sarantopoulos-1861495343

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.uthscsa.edu ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    early therapeutics and genitourinary committees, Southwest Oncology Group

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.uthscsa.edu ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”